Selected research
Industry Research
Direct Acting Antivirals Industry Research Report 2026
Market perspective
The global Direct Acting Antivirals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Direct Acting Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Direct Acting Antivirals is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Direct Acting Antivirals is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Direct Acting Antivirals include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Direct Acting Antivirals market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Direct Acting Antivirals Market by Company
AbbVie
Asegua Therapeutics
Bristol Myers Squibb
Gilead Sciences
Merck
Ascletis Pharma
Cosunter pharmaceutical
Kawin Technology
Sanhome Pharmaceutical
Beijing Sihuan Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Direct Acting Antivirals Segment by Type
Pangenotypic
Genotype-Specific
Direct Acting Antivirals Segment by Application
Hospital and Clinic
Pharmacy
Other
Direct Acting Antivirals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Acting Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Acting Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Acting Antivirals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Direct Acting Antivirals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Direct Acting Antivirals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Direct Acting Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pangenotypic
- Genotype-Specific
Applications
- Hospital and Clinic
- Pharmacy
- Other
Companies covered
- AbbVie
- Asegua Therapeutics
- Bristol Myers Squibb
- Gilead Sciences
- Merck
- Ascletis Pharma
- Cosunter pharmaceutical
- Kawin Technology
- Sanhome Pharmaceutical
- Beijing Sihuan Pharmaceutical
- YiChang HEC ChangJiang Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Direct Acting Antivirals Market Size (2021-2032)
- 2.2.2 Global Direct Acting Antivirals Sales (2021-2032)
- 2.2.3 Global Direct Acting Antivirals Market Average Price (2021-2032)
- 2.3 Direct Acting Antivirals by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pangenotypic
- 2.3.3 Genotype-Specific
- 2.4 Direct Acting Antivirals by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Direct Acting Antivirals Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Direct Acting Antivirals Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Direct Acting Antivirals Revenue of Manufacturers (2021-2026)
- 3.4 Global Direct Acting Antivirals Average Price by Manufacturers (2021-2026)
- 3.5 Global Direct Acting Antivirals Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Direct Acting Antivirals, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Direct Acting Antivirals, Product Type & Application
- 3.8 Global Manufacturers of Direct Acting Antivirals, Established Date
- 3.9 Global Direct Acting Antivirals Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AbbVie
- 4.1.1 AbbVie Company Information
- 4.1.2 AbbVie Business Overview
- 4.1.3 AbbVie Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AbbVie Direct Acting Antivirals Product Portfolio
- 4.1.5 AbbVie Recent Developments
- 4.2 Asegua Therapeutics
- 4.2.1 Asegua Therapeutics Company Information
- 4.2.2 Asegua Therapeutics Business Overview
- 4.2.3 Asegua Therapeutics Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Asegua Therapeutics Direct Acting Antivirals Product Portfolio
- 4.2.5 Asegua Therapeutics Recent Developments
- 4.3 Bristol Myers Squibb
- 4.3.1 Bristol Myers Squibb Company Information
- 4.3.2 Bristol Myers Squibb Business Overview
- 4.3.3 Bristol Myers Squibb Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol Myers Squibb Direct Acting Antivirals Product Portfolio
- 4.3.5 Bristol Myers Squibb Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gilead Sciences Direct Acting Antivirals Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Direct Acting Antivirals Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Ascletis Pharma
- 4.6.1 Ascletis Pharma Company Information
- 4.6.2 Ascletis Pharma Business Overview
- 4.6.3 Ascletis Pharma Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ascletis Pharma Direct Acting Antivirals Product Portfolio
- 4.6.5 Ascletis Pharma Recent Developments
- 4.7 Cosunter pharmaceutical
- 4.7.1 Cosunter pharmaceutical Company Information
- 4.7.2 Cosunter pharmaceutical Business Overview
- 4.7.3 Cosunter pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Cosunter pharmaceutical Direct Acting Antivirals Product Portfolio
- 4.7.5 Cosunter pharmaceutical Recent Developments
- 4.8 Kawin Technology
- 4.8.1 Kawin Technology Company Information
- 4.8.2 Kawin Technology Business Overview
- 4.8.3 Kawin Technology Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kawin Technology Direct Acting Antivirals Product Portfolio
- 4.8.5 Kawin Technology Recent Developments
- 4.9 Sanhome Pharmaceutical
- 4.9.1 Sanhome Pharmaceutical Company Information
- 4.9.2 Sanhome Pharmaceutical Business Overview
- 4.9.3 Sanhome Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanhome Pharmaceutical Direct Acting Antivirals Product Portfolio
- 4.9.5 Sanhome Pharmaceutical Recent Developments
- 4.10 Beijing Sihuan Pharmaceutical
- 4.10.1 Beijing Sihuan Pharmaceutical Company Information
- 4.10.2 Beijing Sihuan Pharmaceutical Business Overview
- 4.10.3 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Beijing Sihuan Pharmaceutical Direct Acting Antivirals Product Portfolio
- 4.10.5 Beijing Sihuan Pharmaceutical Recent Developments
- 4.11 YiChang HEC ChangJiang Pharmaceutical
- 4.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
- 4.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
- 4.11.3 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 YiChang HEC ChangJiang Pharmaceutical Direct Acting Antivirals Product Portfolio
- 4.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
- 4.12 Chia Tai Tianqing Pharmaceutical
- 4.12.1 Chia Tai Tianqing Pharmaceutical Company Information
- 4.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 4.12.3 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Chia Tai Tianqing Pharmaceutical Direct Acting Antivirals Product Portfolio
- 4.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Direct Acting Antivirals Market Scenario by Region
- 5.1 Global Direct Acting Antivirals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Direct Acting Antivirals Sales by Region: 2021-2032
- 5.2.1 Global Direct Acting Antivirals Sales by Region: 2021-2026
- 5.2.2 Global Direct Acting Antivirals Sales by Region: 2027-2032
- 5.3 Global Direct Acting Antivirals Revenue by Region: 2021-2032
- 5.3.1 Global Direct Acting Antivirals Revenue by Region: 2021-2026
- 5.3.2 Global Direct Acting Antivirals Revenue by Region: 2027-2032
- 5.4 North America Direct Acting Antivirals Market Facts & Figures by Country
- 5.4.1 North America Direct Acting Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Direct Acting Antivirals Sales by Country (2021-2032)
- 5.4.3 North America Direct Acting Antivirals Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Direct Acting Antivirals Market Facts & Figures by Country
- 5.5.1 Europe Direct Acting Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Direct Acting Antivirals Sales by Country (2021-2032)
- 5.5.3 Europe Direct Acting Antivirals Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Direct Acting Antivirals Market Facts & Figures by Country
- 5.6.1 Asia Pacific Direct Acting Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Direct Acting Antivirals Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Direct Acting Antivirals Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Direct Acting Antivirals Market Facts & Figures by Country
- 5.7.1 South America Direct Acting Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Direct Acting Antivirals Sales by Country (2021-2032)
- 5.7.3 South America Direct Acting Antivirals Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Direct Acting Antivirals Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Direct Acting Antivirals Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Direct Acting Antivirals Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Direct Acting Antivirals Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Direct Acting Antivirals Sales by Type (2021-2032)
- 6.1.1 Global Direct Acting Antivirals Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Direct Acting Antivirals Sales Market Share by Type (2021-2032)
- 6.2 Global Direct Acting Antivirals Revenue by Type (2021-2032)
- 6.2.1 Global Direct Acting Antivirals Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Direct Acting Antivirals Revenue Market Share by Type (2021-2032)
- 6.3 Global Direct Acting Antivirals Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Direct Acting Antivirals Sales by Application (2021-2032)
- 7.1.1 Global Direct Acting Antivirals Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Direct Acting Antivirals Sales Market Share by Application (2021-2032)
- 7.2 Global Direct Acting Antivirals Revenue by Application (2021-2032)
- 7.2.1 Global Direct Acting Antivirals Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Direct Acting Antivirals Revenue Market Share by Application (2021-2032)
- 7.3 Global Direct Acting Antivirals Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Direct Acting Antivirals Value Chain Analysis
- 8.1.1 Direct Acting Antivirals Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Direct Acting Antivirals Production Mode & Process
- 8.2 Direct Acting Antivirals Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Direct Acting Antivirals Distributors
- 8.2.3 Direct Acting Antivirals Customers
9 Global Direct Acting Antivirals Analyzing Market Dynamics
- 9.1 Direct Acting Antivirals Industry Trends
- 9.2 Direct Acting Antivirals Industry Drivers
- 9.3 Direct Acting Antivirals Industry Opportunities and Challenges
- 9.4 Direct Acting Antivirals Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst